United Therapeutics Corp. (UTHR) Stock Price Down 2.2%
United Therapeutics Corp. (NASDAQ:UTHR)’s share price dropped 2.2% during trading on Friday . The company traded as low as $119.70 and last traded at $120.59, with a volume of 287,307 shares trading hands. The stock had previously closed at $123.26.
UTHR has been the topic of a number of research reports. Wedbush reissued an “outperform” rating and issued a $229.00 target price on shares of United Therapeutics Corp. in a research note on Thursday, July 28th. HC Wainwright reissued a “hold” rating on shares of United Therapeutics Corp. in a research note on Friday, July 29th. Zacks Investment Research raised shares of United Therapeutics Corp. from a “hold” rating to a “strong-buy” rating and set a $125.00 target price on the stock in a research note on Tuesday, July 5th. Argus downgraded shares of United Therapeutics Corp. from a “buy” rating to a “hold” rating and set a $114.00 target price on the stock. in a research note on Tuesday, May 24th. Finally, Ladenburg Thalmann downgraded shares of United Therapeutics Corp. from a “buy” rating to a “neutral” rating in a research note on Friday, April 29th. Nine equities research analysts have rated the stock with a hold rating and three have issued a buy rating to the company’s stock. United Therapeutics Corp. currently has a consensus rating of “Hold” and a consensus target price of $135.64.
The company has a market capitalization of $5.29 billion and a P/E ratio of 5.89. The firm has a 50 day moving average of $119.49 and a 200-day moving average of $116.50.
United Therapeutics Corp. (NASDAQ:UTHR) last posted its earnings results on Thursday, July 28th. The biotechnology company reported $4.55 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $3.22 by $1.33. During the same period in the prior year, the firm earned $2.55 earnings per share. The business earned $412.60 million during the quarter, compared to the consensus estimate of $395.15 million. The business’s revenue was up 18.8% on a year-over-year basis. On average, analysts forecast that United Therapeutics Corp. will post $15.82 earnings per share for the current fiscal year.
In related news, CEO Martine A. Rothblatt sold 1,312 shares of the company’s stock in a transaction on Thursday, June 23rd. The shares were sold at an average price of $104.07, for a total transaction of $136,539.84. Following the completion of the transaction, the chief executive officer now directly owns 1,552 shares in the company, valued at approximately $161,516.64. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, CEO Martine A. Rothblatt sold 1,249 shares of the company’s stock in a transaction on Thursday, August 18th. The shares were sold at an average price of $125.88, for a total transaction of $157,224.12. Following the transaction, the chief executive officer now owns 1,389 shares of the company’s stock, valued at $174,847.32. The disclosure for this sale can be found here.
An institutional investor recently raised its position in United Therapeutics Corp. stock. State of Tennessee Treasury Department increased its stake in shares of United Therapeutics Corp. (NASDAQ:UTHR) by 29.9% during the fourth quarter, according to its most recent disclosure with the SEC. The institutional investor owned 86,900 shares of the biotechnology company’s stock after buying an additional 20,000 shares during the period. State of Tennessee Treasury Department owned approximately 0.19% of United Therapeutics Corp. worth $13,609,000 as of its most recent filing with the SEC.
United Therapeutics Corporation is a biotechnology company. The Company is focused on the development and commercialization of products for the treatment of chronic and life-threatening conditions. Its therapeutic products and product candidates include Prostacyclin Analogues, Phosphodiesterase Type 5 (PDE-5) Inhibitor and Monoclonal Antibody (MAb).
Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.